Tumor Regression In Vivo by Photothermal Therapy Based on Gold-Nanorod-Loaded, Functional Nanocarriers

ACS Nano ◽  
2011 ◽  
Vol 5 (3) ◽  
pp. 1995-2003 ◽  
Author(s):  
Won Il Choi ◽  
Ja-Young Kim ◽  
Chul Kang ◽  
Clare C. Byeon ◽  
Young Ha Kim ◽  
...  
Keyword(s):  
Photothermal Therapy ◽  
Tumor Regression ◽  
Gold Nanorod

Gold Nanorod−Photosensitizer Complex for Near-Infrared Fluorescence Imaging and Photodynamic/Photothermal Therapy In Vivo

ACS Nano ◽  
2011 ◽  
Vol 5 (2) ◽  
pp. 1086-1094 ◽  
Author(s):  
Boseung Jang ◽  
Jin-Young Park ◽  
Ching-Hsuan Tung ◽  
In-Hoo Kim ◽  
Yongdoo Choi
Keyword(s):  
Fluorescence Imaging ◽  
Photothermal Therapy ◽  
Near Infrared ◽  
Gold Nanorod ◽  
Near Infrared Fluorescence ◽  
Near Infrared Fluorescence Imaging

DNA-Nanostructure-Gold-Nanorod Hybrids for Enhanced In Vivo Optoacoustic Imaging and Photothermal Therapy

2016 ◽  
Vol 28 (45) ◽  
pp. 10000-10007 ◽  
Author(s):  
Yang Du ◽  
Qiao Jiang ◽  
Nicolas Beziere ◽  
Linlin Song ◽  
Qian Zhang ◽  
...  
Keyword(s):  
Photothermal Therapy ◽  
Gold Nanorod ◽  
Optoacoustic Imaging ◽  
Dna Nanostructure

scholarly journals Gold Nanorod-Assisted Photothermal Therapy Decreases Bleeding during Breast Cancer Surgery in Dogs and Cats

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 851 ◽  
Author(s):  
Moustafa R. K. Ali ◽  
Haithem A. M. Farghali ◽  
Yue Wu ◽  
Ivan El-Sayed ◽  
Ahmed H. Osman ◽  
...  
Keyword(s):  
Blood Vessels ◽  
Photothermal Therapy ◽  
Near Infrared ◽  
Tumor Regression ◽  
Gold Nanorod ◽  
Breast Cancer Surgery ◽  
Infrared Light ◽  
Group I ◽  
Group Ii ◽  
Risk Of Cancer

For localized tumors, gold nanorod (AuNR)-assisted plasmonic photothermal therapy (PPTT) is a potentially effective alternative to traditional surgery, in which AuNRs absorb near-infrared light and convert it to heat in order to kill cancer cells. However, for large tumors (volume ≥ 20 cm3), an uneven distribution of AuNRs might cause inhomogeneity of the heat distribution inside the tumor. Surgery is frequently recommended for removing large tumors, but it is associated with a high risk of cancer recurrence and metastasis. Here, we applied PPTT before surgery, which showed improved treatment for large tumors. We divided the animals (eight cats/dogs) into two groups: Group I (control), where three cases were solely treated with surgery, laser, or AuNRs alone, resulting in recurrence and metastasis; and Group II, where animals were treated with PPTT before surgery. In Group II, four out of the five cases had tumor regression without any recurrence or metastasis. Interestingly, we observed that applying PPTT before surgery displayed reduced bleeding during tumor removal, supported by histopathology that showed altered blood vessels. In conclusion, our study showed that applying AuNR-assisted PPTT (AuNRs-PPTT) before surgery could significantly affect blood vessels inside the tumor, leading to a decreased amount of bleeding during surgery, which can potentially decrease the risk of metastasis and blood loss during surgery.

Chitosan coated gold nanorod chelating gadolinium for MRI-visible photothermal therapy of cancer

RSC Advances ◽  
2016 ◽  
Vol 6 (112) ◽  
pp. 111337-111344 ◽  
Author(s):  
Chunyang Zhang ◽  
Fang Zhang ◽  
Wei Wang ◽  
Jie Liu ◽  
Ming Xu ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Photothermal Therapy ◽  
Gold Nanorod ◽  
Multifunctional Nanoparticles

The multifunctional nanoparticles synthesized via nonsolvent counterion complexation method are applied for in vivo MR imaging and photothermal therapy of cancer.

MicroCT Imaging and In Vivo Temperature Elevations in Implanted Prostatic Tumors in Laser Photothermal Therapy Using Gold Nanorods

2012 ◽  
Vol 3 (2) ◽  
Author(s):  
N. Manuchehrabadi ◽  
A. Attaluri ◽  
H. Cai ◽  
R. Edziah ◽  
E. Lalanne ◽  
...  
Keyword(s):  
Gold Nanorods ◽  
Photothermal Therapy ◽  
Imaging System ◽  
Laser Energy ◽  
Gold Nanorod ◽  
Laser Irradiance ◽  
Theoretical Simulation ◽  
Microct Imaging ◽  
Laser Photothermal Therapy

In this study, in vivo animal experiments are performed on implanted xenograph prostatic tumors in nude mice to investigate enhanced laser energy absorption in the tumors by an intratumoral injection of gold nanorod solutions. In vivo temperature mapping of the tumors during laser photothermal therapy has shown the feasibility of elevating tumor temperatures higher than 50 °C using only 0.1 ml nanorod solution and a low laser irradiance of 1.6 W/cm2 incident on the tumor surface. The temperature profile suggests that normal tumor tissue still absorbs some amount of the laser energy without nanorod presence; however, the injected nanorods ensure that almost all the laser energy is absorbed and confined to the targeted tumors. The inverse relationship between the temperature elevations and the tumor size implies a relatively uniform spreading of the nanorods to the entire tumor, which is also shown by microcomputed tomography (microCT) imaging analyses. The feasibility of detecting 250 OD gold nanorod solution injected to the tumors is demonstrated via a high resolution microCT imaging system. Compared to other nanostructures, the gold nanorods used in this study do not accumulate surrounding the injection site. The relatively uniform deposition of the nanorods in the tumors observed by the microCT scans can be helpful in future study in simplifying theoretical simulation of temperature elevations in tumors during laser photothermal therapy.

NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression

2013 ◽  
Vol 13 (5) ◽  
pp. 777-790 ◽  
Author(s):  
Yasrib Qurishi ◽  
Abid Hamid ◽  
Parduman R. Sharma ◽  
Zahoor A. Wani ◽  
Dilip M. Mondhe ◽  
...  
Keyword(s):  
Cancer Cell ◽  
Tumor Regression ◽  
Parp Cleavage ◽  
Boswellic Acid ◽  
Down Regulation

scholarly journals A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Katherine E. Harris ◽  
Kyle J. Lorentsen ◽  
Harbani K. Malik-Chaudhry ◽  
Kaitlyn Loughlin ◽  
Harish Medlari Basappa ◽  
...  
Keyword(s):  
T Cells ◽  
Nk Cells ◽  
Bispecific Antibody ◽  
T Regulatory Cells ◽  
Tumor Regression ◽  
Interleukin 2 ◽  
In Vivo Studies ◽  
Preferential Binding

AbstractThe use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 treatment are due to the preferential binding of IL-2 to cells that express the high-affinity, trimeric receptor, IL-2Rαβγ such as endothelial cells and T-regulatory cells, respectively. Here, we describe a novel bispecific heavy-chain only antibody which binds to and activates signaling through the heterodimeric IL-2Rβγ receptor complex that is expressed on resting T-cells and NK cells. By avoiding binding to IL-2Rα, this molecule circumvents the preferential T-reg activation of native IL-2, while maintaining the robust stimulatory effects on T-cells and NK-cells in vitro. In vivo studies in both mice and cynomolgus monkeys confirm the molecule’s in vivo biological activity, extended pharmacodynamics due to the Fc portion of the molecule, and enhanced safety profile. Together, these results demonstrate that the bispecific antibody is a safe and effective IL-2R agonist that harnesses the benefits of the IL-2 signaling pathway as a potential anti-cancer therapy.

scholarly journals Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3375
Author(s):  
Annabelle Vogt ◽  
Farsaneh Sadeghlar ◽  
Tiyasha H. Ayub ◽  
Carlo Schneider ◽  
Christian Möhring ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
T Cells ◽  
Dendritic Cells ◽  
Tumor Regression ◽  
Combined Therapy ◽  
Term Survival ◽  
Effector Cells ◽  
Tumor Environment ◽  
The Impact

Dendritic cells (DC) as professional antigen presenting cells are able to prime T-cells against the tumor-associated antigen α-fetoprotein (AFP) for immunotherapy of hepatocellular carcinoma (HCC). However, a strong immunosuppressive tumor environment limits their efficacy in patients. The co-stimulation with CD40Ligand (CD40L) is critical in the maturation of DC and T-cell priming. In this study, the impact of intratumoral (i.t.) CD40L-expressing DC to improve vaccination with murine (m)AFP-transduced DC (Ad-mAFP-DC) was analyzed in subcutaneous (s.c.) and orthotopic murine HCC. Murine DC were adenovirally transduced with Ad-mAFP or Ad-CD40L. Hepa129-mAFP-cells were injected into the right flank or the liver of C3H-mice to induce subcutaneous (s.c.) and orthotopic HCC. For treatments, 106 Ad-mAFP-transduced DC were inoculated s.c. followed by 106 CD40L-expressing DC injected intratumorally (i.t.). S.c. inoculation with Ad-mAFP-transduced DC, as vaccine, induced a delay of tumor-growth of AFP-positive HCC compared to controls. When s.c.-inoculation of Ad-mAFP-DC was combined with i.t.-application of Ad-CD40L-DC synergistic antitumoral effects were observed and complete remissions and long-term survival in 62% of tumor-bearing animals were achieved. Analysis of the tumor environment at different time points revealed that s.c.-vaccination with Ad-mAFP-DC seems to stimulate tumor-specific effector cells, allowing an earlier recruitment of effector T-cells and a Th1 shift within the tumors. After i.t. co-stimulation with Ad-CD40L-DC, production of Th1-cytokines was strongly increased and accompanied by a robust tumor infiltration of mature DC, activated CD4+-, CD8+-T-cells as well as reduction of regulatory T-cells. Moreover, Ad-CD40L-DC induced tumor cell apoptosis. Intratumoral co-stimulation with CD40L-expressing DC significantly improves vaccination with Ad-mAFP-DC in pre-established HCC in vivo. Combined therapy caused an early and strong Th1-shift in the tumor environment as well as higher tumor apoptosis, leading to synergistic tumor regression of HCC. Thus, CD40L co-stimulation represents a promising tool for improving DC-based immunotherapy of HCC.

scholarly journals In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1051
Author(s):  
Christopher Montemagno ◽  
Florian Raes ◽  
Mitra Ahmadi ◽  
Sandrine Bacot ◽  
Marlène Debiossat ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Tumor Volume ◽  
Tumor Regression ◽  
Efficacy Evaluation ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Target Organs ◽  
G Protein Coupled ◽  
Complete Tumor

NeoB is a radiotracer targeting the gastrin-releasing peptide receptor (GRPR), a G-protein–coupled receptor expressed in various cancers. The aim of the present study was to evaluate the biodistribution and efficacy of this new therapeutic agent in Gastrointestinal Stromal Tumors (GIST). Eighty-two SCID mice bearing GIST-882 tumors were employed. [177Lu]Lu-NeoB biodistribution was evaluated up to seven days by organ sampling (200 pmol/0.8 MBq, i.v.). For efficacy evaluation, mice received either saline, 400 pmol or 800 pmol of [177Lu]Lu-NeoB (37MBq, 1/w, 3 w, i.v.). SPECT/CT imaging was performed at 24 h, and tumor volume was determined up to 100 days. Elevated and specific [177Lu]Lu-NeoB uptake was found in the GIST tumor, as demonstrated by in vivo competition (19.1 ± 3.9 %ID/g vs. 0.3 ± 0.1 %ID/g at 4h). [177Lu]Lu-NeoB tumor retention (half-life of 40.2 h) resulted in elevated tumor-to-background ratios. Tumor volumes were significantly reduced in both treated groups (p < 0.01), even leading to complete tumor regression at the 400 pmol dose. [177Lu]Lu-NeoB exhibited excellent pharmacokinetics with elevated and prolonged tumor uptake and low uptake in non-target organs such as pancreas. The potential of this new theragnostic agent in different indications, including GIST, is under evaluation in the FIH [177Lu]Lu-NeoB clinical trial.

Sign in / Sign up

Export Citation Format

Share Document